Research | Search for research projects | Reducing emergency caesarean birth for fetal distress in women with small or poorly grown infants using Sildenafil Citrate – The RidStress 2 Randomised Controlled Trial

Reducing emergency caesarean birth for fetal distress in women with small or poorly grown infants using Sildenafil Citrate – The RidStress 2 Randomised Controlled Trial

Project Status In Progress
Organisation Lead Mater Research
Lead Investigators Sailesh Kumar
Program Area New Approaches To Prevention
Topic Testing Novel Interventions To Reduce Stillbirth Rates

Aim
RidStress2 is a consumer-informed, double-blind, Phase 3 randomised controlled trial (RCT) in 300 women with SGA or suboptimally grown fetuses at term (Population) to test if SC (Intervention) vs placebo (Comparator) (i) reduces the relative risk of emergency CS for fetal distress by 33% (Primary Outcome) (ii) improves childhood neurodevelopmental outcomes at 2 years; and (iii) is cost-effective.

Progress
Recruitment of 282 participants across four south-east Queensland hospitals is now complete. Data analysis is in progress, as well as neurodevelopmental outcome follow up for the children of participants.

Publications
Triggs T, Badawi N, Crawford K, Liley H, Lehner C, Nugent R, et al. RidStress 2 randomised controlled trial protocol: an Australian phase III clinical trial of intrapartum sildenafil citrate or placebo to reduce emergency caesarean birth for fetal distress in women with small or suboptimally grown infants at term (≥37 weeks). BMJ Open. 2024;14(9):e082945.

Western Pacific Regional Office of the International Stillbirth Alliance
Coordinating Centre, Stillbirth and Neonatal Death Alliance, Perinatal Society of Australia and New Zealand

Level 3, Aubigny Place
Mater Research Institute
Raymond Terrace,
South Brisbane QLD 4101
The University of Queensland Faculty of Medicine

Copyright © Stillbirth CRE